Travere Therapeutics Analyst Ratings
Travere Therapeutics Analyst Ratings
Travere Therapeutics Analyst Ratings
Wedbush Lifts Travere Therapeutics' Price Target to $13 From $12, Keeps Outperform Rating
Travere Therapeutics Analyst Ratings
Travere Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Raises Price Target to $20
Travere Therapeutics Analyst Ratings
Stifel Nicolaus Sticks to Its Hold Rating for Travere Therapeutics (TVTX)
Citigroup Upgrades Travere Therapeutics to Buy, Raises Price Target to $10
HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $18 Price Target
Travere Therapeutics Analyst Ratings
JPMorgan Adjusts Travere Therapeutics Price Target to $19 From $23, Maintains Overweight Rating
Citigroup Initiates Coverage On Travere Therapeutics With Neutral Rating, Announces Price Target of $7
Travere Therapeutics Analyst Ratings
Travere Therapeutics Analyst Ratings
Canaccord Genuity Cuts Travere Therapeutics Price Target to $15 From $35, Maintains Buy Rating
Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $12 Price Target
Travere Therapeutics Analyst Ratings
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Lowers Price Target to $14
No Data